Gilead Sciences, Inc. (GILD)财务
NASDAQ · Healthcare · Drug Manufacturers - General · 员工17,000人 · CEO Daniel O'Day
- 股价
- $170.68 +3.06%
- 市值
- $2120亿
- 企业价值
- $2310亿
- 最近财报
- Q3 '26 2026-10-30提交
- 下次财报
- 2027-02-09 EPS预期 $1.39
营收(TTM)$310亿+6.5% 对比去年同期最近4个季度;柱状图=各季度
营业利润率(TTM)-4.4%-40.4 百分点 对比去年同期营业利润 -$13.6亿
净利润(TTM)-$38.6亿-147.6% 对比去年同期税后,含营业外收益
自由现金流(TTM)$140亿+53.2% 对比去年同期资本支出 $4.42亿
稀释EPS(TTM)-$3.16-149.0% 对比去年同期最近4个季度之和
净现金-$198亿-12.5% 对比去年同期现金 + 短期投资 - 债务
估值与关键数据
- 市值
- $2120亿 EV $2310亿
- 营收
- $310亿 过去12个月
- 营收增速
- +6% FY2026年一致预期
- 净利润率
- -12.5% 净利润 / 营收,TTM
- P/E
- -55.1× 预期 -213.4×(FY2026)
- P/S
- 6.8× 股价 / 营收,TTM
- EV / EBITDA
- 281.2× TTM
- 自由现金流
- $140亿 过去12个月
- 净利润
- -$38.6亿 过去12个月
- 营收预期
- $312亿 FY2026年一致预期
- 盈利
- 2027-02-09 营收预期 $82.8亿
- 股息
- $3.25 每股,过去12个月
核心要点
根据披露数据计算,每条结论都附有其依据的数字。
- 最近财报(2026-10-29):营收超预期6.3%,EPS 超预期16.4%营收$83亿,预期$78.1亿(+6.3%);EPS $2.55,预期$2.19(+16.4%)。
- 营收增长加速:同比6.8%Q3 '26营收$83亿,此前四个季度的平均值为5.6%。
- 营业利润率-4.4%(TTM),较去年同期-40.4 百分点营收增长6.5%,营业利润增长-112.9%。
- 资本支出占营收的1.4%(去年为1.7%)最近4个季度投入$4.42亿(同比-12.5%)。自由现金流$140亿。
- 股东回报$54.8亿 = 自由现金流的39.0%回购$13.7亿(去年为$20.4亿),股息$41亿,股权激励$4.64亿(TTM)。
- 稀释股数一年内减少0.2%Q3 '26稀释股数12.5亿,一年前为12.5亿。
- 净债务 $198亿现金 + 短期投资 $64.4亿,含租赁债务 $262亿;一年前净债务 $176亿。
上一季度:Q3 '26
截至2026-09-30的季度。与去年同期及财报发布前的分析师一致预期对比。
本季度与去年同期
| Q3 '26 | 去年同期 | 变化 | |
|---|---|---|---|
| 营收 | $83亿 | $77.7亿 | +6.8% |
| 毛利率 | 81.1% | 79.8% | +1.3 百分点 |
| 营业利润 | $34.6亿 | $33.3亿 | +4.1% |
| 营业利润率 | 41.7% | 42.8% | -1.1 百分点 |
| 净利润 | $24.3亿 | $30.5亿 | -20.4% |
| 稀释EPS | $1.94 | $2.43 | -20.2% |
| 经营现金流 | $50.4亿 | $41.1亿 | +22.6% |
| 资本支出 | $2.37亿 | $1.47亿 | +61.2% |
| 自由现金流 | $48亿 | $39.6亿 | +21.2% |
| R&D | $16.1亿 | $13.5亿 | +19.5% |
| 股权激励费用 | $2.34亿 | $2.3亿 | +1.7% |
实际 vs 一致预期
2026-10-29| 实际 | 一致预期 | 对比预期 | |
|---|---|---|---|
| 营收 | $83亿 | $78.1亿 | +6.3% |
| EPS(一致预期口径) | $2.55 | $2.19 | +16.4% |
来自2026-10-29发布的Q3 '26财报：营收及分析师预期口径的EPS（通常为调整后），可能与上方报表中的EPS不同。
EPS与一致预期
最近8次财报营收
收入从何而来,按业务线和地区逐季展示。
营收、营业利润与增速
季度按业务线划分的营收
堆叠,季度| 分部 | Q3 '26 | 同比 | 占比 | TTM | TTM同比 | 12个季度 |
|---|---|---|---|---|---|---|
| Products, Other HIV | $62.5亿 | +18.4% | 84.2% | – | – | |
| Total HIV | – | – | – | – | – | |
| Cell Therapy Products, Total Cell Therapy Product Sales | $4.15亿 | -19.4% | 5.6% | – | – | |
| Total Liver Disease | – | – | – | – | – | |
| Total Oncology | – | – | – | – | – | |
| Veklury | $8600万 | -69.0% | 1.2% | $4.64亿 | -62.9% | |
| Trodelvy | $5.06亿 | +41.7% | 6.8% | – | – | |
| Other Products, Total Other product sales | $1.67亿 | -9.2% | 2.2% | – | – | |
| Total Other | – | – | – | – | – | |
| Royalty, contract and other revenues | – | – | – | – | – |
按地区划分的营收
占总额比例| 分部 | Q3 '26 | 同比 | 占比 | TTM | TTM同比 | 12个季度 |
|---|---|---|---|---|---|---|
| United States | $63.6亿 | +20.5% | 76.7% | $225亿 | +8.5% | |
| Europe | $10.7亿 | -31.5% | 12.8% | $47.7亿 | -4.7% | |
| Other International | $8.72亿 | -6.5% | 10.5% | $34.5亿 | -1.9% |
利润率与成本结构
每一单位营收在各层级还剩多少,成本又花在哪里。
利润率
季度成本占营收比例
季度现金流与资本配置
创造了多少现金,用在何处,又有多少回到股东手中。
经营现金流、资本支出、自由现金流
季度现金用途与经营现金流
财年最近4个季度
现金流量表- 经营现金流
- $145亿
- 资本支出
- -$4.42亿
- 股票回购
- -$13.7亿
- 股息
- -$41亿
- 收购
- -$6.28亿
- 债务净发行
- $12.8亿
- 股权激励费用
- $4.64亿
- 自由现金流
- $140亿
- 股东回报 / FCF
- 39.0%
股数与EPS
季度,稀释资产负债表
各季度末的流动性、投资和债务。
现金、投资与债务
季度末估值与回报
当前估值倍数与公司自身过去五个财年对比;分析师目标价与评级。
估值倍数与回报
TTM与过去5个财年| 当前 | 5年均值 | 当前处于5年区间的位置 | |
|---|---|---|---|
| P/E(TTM) | -55.1× | 63.4× | 14.6× – 243.1× |
| EV / EBITDA | 281.2× | 15.6× | 9.9× – 29.7× |
| EV / 营收 | 7.5× | 4.7× | 4.1× – 5.8× |
| 股价 / FCF | 15.1× | 12.5× | 8.4× – 16.1× |
| 股价 / 净资产 | 16.3× | 5.3× | 4.3× – 6.7× |
| FCF收益率 | 6.6% | 8.4% | 6.2% – 11.8% |
| 投入资本回报率 | -3.2% | 11.6% | 2.4% – 20.3% |
| 净资产收益率 | -21.7% | 23.2% | 2.5% – 37.5% |
分析师
一致目标价 $163.67 (-4.1%)
区间 $126.00 – $195.00 · 评级 Buy
强烈买入0
买入38
持有19
卖出1
强烈卖出0
展望
分析师对未来财年的一致预期,以及按当前股价意味着什么。
一致预期
| 财年 | 营收 | 增速 | EPS | 增速 | 按当前股价的P/E | 分析师(EPS) |
|---|---|---|---|---|---|---|
| FY2026 | $312亿 | +6.0% | -$0.80 | -111.8% | -213.4× | 11 |
| FY2027 | $334亿 | +7.0% | $10.07 | +1,359.8% | 16.9× | 16 |
| FY2028 | $348亿 | +4.0% | $10.78 | +7.0% | 15.8× | 10 |
| FY2029 | $373亿 | +7.4% | $12.20 | +13.1% | 14.0× | 4 |
| FY2030 | $396亿 | +6.1% | $13.35 | +9.4% | 12.8× | 4 |
财务报表
利润表、资产负债表和现金流量表的每一项,含12个季度和10个财年,以金额、占营收比例或增速展示。
全部披露项目
Gilead Sciences, Inc.在近期10-Q / 10-K文件中标记的全部275项数据,附SEC官方标签和定义,包括附注(租赁、税务、回购、员工等)。
| 项目(SEC标签) | 最近季度 | 去年同期 | 同比 | 最近财年 | 上一财年 | 同比 |
|---|---|---|---|---|---|---|
| Accounts Payable, Current | $9.34亿 | $8.08亿 | +15.6% | $7.15亿 | $8.33亿 | -14.2% |
| Accounts Receivable, after Allowance for Credit Loss, Current | $50.1亿 | $51亿 | -1.7% | $49.1亿 | $44.2亿 | +11.2% |
| Accounts Receivable, Allowance for Credit Loss, Current | $4200万 | $4100万 | +2.4% | $4100万 | $5200万 | -21.2% |
| Accounts Receivable, before Allowance for Credit Loss, Current | $59.6亿 | $59.9亿 | -0.6% | $59亿 | $53.2亿 | +10.8% |
| Accrued Income Taxes, Current | $9200万2025-12-31 | $16.5亿 | -94.4% | $9200万 | $16.5亿 | -94.4% |
| Accrued Income Taxes, Noncurrent | $9.74亿 | $8.66亿 | +12.5% | $8.96亿 | $8.3亿 | +8.0% |
| Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | $30亿 | $26.9亿 | +11.4% | $27亿 | $24.7亿 | +9.1% |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | $8900万 | $3600万 | +147.2% | $3900万 | $1.32亿 | -70.5% |
| Additional Paid in Capital | $98.4亿 | $86.8亿 | +13.4% | $89.3亿 | $77亿 | +16.0% |
| Advertising Expense | – | – | – | $10亿 | $8.69亿 | +15.1% |
| Amortization | $6.08亿 | $5.96亿 | +2.0% | $23.9亿 | $23.9亿 | +0.2% |
| Amortization of Intangible Assets | – | – | – | $24亿 | $24亿 | 0.0% |
| Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 100万 | 300万 | -66.7% | 200万 | 500万 | -60.0% |
| APIC, Share-based Payment Arrangement, Increase for Cost Recognition | $2.34亿 | $2.31亿 | +1.3% | $8.99亿 | $8.34亿 | +7.8% |
| Assets | $514亿 | $585亿 | -12.2% | $590亿 | $590亿 | 0.0% |
| Assets, Current | $166亿 | $179亿 | -7.4% | $183亿 | $192亿 | -4.3% |
| Assets, Fair Value Disclosure | $64.8亿 | – | – | $69.7亿2020-12-31 | $110亿 | -36.9% |
| Buildings and Improvements, Gross | $46.2亿2025-12-31 | $45.4亿 | +1.8% | $46.2亿 | $45.4亿 | +1.8% |
| Capitalized Computer Software, Gross | $6.66亿2025-12-31 | $6.92亿 | -3.8% | $6.66亿 | $6.92亿 | -3.8% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $64.4亿 | $73.3亿 | -12.2% | $75.6亿 | $99.9亿 | -24.3% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | $32.6亿 | $21.9亿 | +49.0% | -$24.3亿 | $39.1亿 | -162.2% |
| Common Stock, Dividends, Per Share, Declared | $0.82 | $0.79 | +3.8% | $3.16 | $3.08 | +2.6% |
| Common Stock, Par or Stated Value Per Share | $0.00 | $0.00 | 0.0% | $0.00 | $0.00 | 0.0% |
| Common Stock, Shares Authorized | 56亿 | 56亿 | 0.0% | 56亿 | 56亿 | 0.0% |
| Common Stock, Shares, Issued | 12.4亿 | 12.4亿 | -0.1% | 12.4亿 | 12.5亿 | -0.4% |
| Common Stock, Shares, Outstanding | 12.4亿 | 12.4亿 | -0.1% | 12.4亿 | 12.5亿 | -0.4% |
| Common Stock, Value, Issued | $100万 | $100万 | 0.0% | $100万 | $100万 | 0.0% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest | $02025-12-31 | $0 | – | $0 | $0 | – |
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | $24.2亿 | $31.1亿 | -22.0% | $84.2亿 | $5.84亿 | +1,341.4% |
| Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest | $21.9亿2025-12-31 | $18.4亿 | +18.7% | $84.2亿 | $5.84亿 | +1,341.4% |
| Construction in Progress, Gross | $7.45亿2025-12-31 | $5.01亿 | +48.7% | $7.45亿 | $5.01亿 | +48.7% |
| Contract with Customer, Asset, after Allowance for Credit Loss | $7.32亿 | $6.95亿 | +5.3% | $6.29亿 | $2.77亿 | +127.1% |
| Contract with Customer, Liability | $5700万 | $5600万 | +1.8% | $4800万 | $5800万 | -17.2% |
| Contract with Customer, Performance Obligation Satisfied in Previous Period | $1.46亿 | $1.48亿 | -1.4% | $6.12亿 | $7.27亿 | -15.8% |
| Contract with Customer, Refund Liability, Current | $3.21亿2025-12-31 | $3.21亿 | 0.0% | $3.21亿 | $3.21亿 | 0.0% |
| Cost of Goods and Services Sold | $15.7亿 | $15.7亿 | +0.1% | $62.3亿 | $62.5亿 | -0.3% |
| Costs and Expenses | $48.4亿 | $44.4亿 | +8.9% | $194亿 | $271亿 | -28.3% |
| Current Federal Tax Expense (Benefit) | – | – | – | $8.2亿 | $15亿 | -45.2% |
| Current Foreign Tax Expense (Benefit) | – | – | – | $2.56亿 | $5.19亿 | -50.7% |
| Current State and Local Tax Expense (Benefit) | – | – | – | $5100万 | $3900万 | +30.8% |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax | $100万2026-03-31 | – | – | $1100万 | – | – |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | $400万2026-03-31 | – | – | $100万 | – | – |
| Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10 | $02025-09-30 | – | – | $200万2023-12-31 | $600万 | -66.7% |
| Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 | $400万2026-03-31 | – | – | $3200万 | – | – |
| Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five | $9.82亿2026-03-31 | – | – | $29.3亿 | – | – |
| Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One | $1500万2026-03-31 | – | – | $7000万 | – | – |
| Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer | – | – | – | $6.24亿2023-12-31 | $7.05亿 | -11.5% |
| Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss | – | – | – | $800万2023-12-31 | $1200万 | -33.3% |
| Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months | $6.69亿2026-03-31 | – | – | $7.24亿 | – | – |
| Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss | – | – | – | $200万2023-12-31 | $2200万 | -90.9% |
| Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10 | $02025-09-30 | – | – | $200万2023-12-31 | $600万 | -66.7% |
| Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 | $400万2026-03-31 | – | – | $3200万 | – | – |
| Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five | $9.79亿2026-03-31 | – | – | $29.4亿 | – | – |
| Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One | $1500万2026-03-31 | – | – | $7000万 | – | – |
| Debt Securities, Available-for-sale, Unrealized Loss Position | – | – | – | $13.5亿2023-12-31 | $19.1亿 | -29.2% |
| Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss | – | – | – | $1000万2023-12-31 | $3400万 | -70.6% |
| Debt, Current | $24.2亿 | $28.1亿 | -13.9% | $28.1亿 | $18.2亿 | +54.7% |
| DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss | $10亿2026-03-31 | – | – | $30.3亿 | $0 | – |
| DebtSecuritiesAvailableForSaleExcludingAccruedInterest | $9.97亿2026-03-31 | – | – | $30.4亿 | – | – |
| Deferred Compensation Arrangement with Individual, Compensation Expense | – | – | – | $2亿 | $2.04亿 | -2.0% |
来源:SEC companyfacts(每份10-Q / 10-K的XBRL)。现金流量表的季度数据由10-Q标记的年初至今累计数推算。分部拆分带有维度标记,在分部章节中单独展示。
数据来源
报表、分部营收、指标、预期:Financial Modeling Prep。分部利润及全部披露项目:SEC EDGAR(XBRL)。 已读取的文件: 10-Q 2026-09-30, 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30
数据截至 2026-11-01